Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-02-09

AUTHORS

Hiroyoshi Yokoi, Eisei Oda, Kazuki Kaneko, Kenta Matsubayashi

ABSTRACT

In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012–March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3 months post-PCI. Patients without major efficacy or safety events within 3 months after index PCI were included in a landmark analysis set (LAS; n = 7056), and categorized as DAPT ≥ 3 months (continuation) versus < 3 months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P = 0.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P < 0.001). In multivariate regression analysis, age ≥ 75 years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk. More... »

PAGES

465-474

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z

DOI

http://dx.doi.org/10.1007/s12928-021-00833-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1145403453

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35141843


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Infarction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Percutaneous Coronary Intervention", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "International University of Health and Welfare, Tochigi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411731.1", 
          "name": [
            "Cardiovascular Medicine Center, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, 814-0001, Fukuoka, Japan", 
            "International University of Health and Welfare, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yokoi", 
        "givenName": "Hiroyoshi", 
        "id": "sg:person.01052603744.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "StatLink Medical Statistics Consulting Service, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "StatLink Medical Statistics Consulting Service, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oda", 
        "givenName": "Eisei", 
        "id": "sg:person.016464605275.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016464605275.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaneko", 
        "givenName": "Kazuki", 
        "id": "sg:person.013473141311.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473141311.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410844.d", 
          "name": [
            "Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsubayashi", 
        "givenName": "Kenta", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrcardio.2014.104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039569766", 
          "https://doi.org/10.1038/nrcardio.2014.104"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-020-01708-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1129531993", 
          "https://doi.org/10.1007/s00392-020-01708-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11239-018-1707-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105133084", 
          "https://doi.org/10.1007/s11239-018-1707-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-02-09", 
    "datePublishedReg": "2022-02-09", 
    "description": "In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012\u2013March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3\u00a0months post-PCI. Patients without major efficacy or safety events within 3\u00a0months after index PCI were included in a landmark analysis set (LAS; n\u2009=\u20097056), and categorized as DAPT\u2009\u2265\u20093\u00a0months (continuation) versus\u2009<\u20093\u00a0months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P\u2009=\u20090.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P\u2009<\u20090.001). In multivariate regression analysis, age\u2009\u2265\u200975\u00a0years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12928-021-00833-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1042779", 
        "issn": [
          "1868-4300", 
          "1868-4297"
        ], 
        "name": "Cardiovascular Intervention and Therapeutics", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "dual antiplatelet therapy", 
      "percutaneous coronary intervention", 
      "composite efficacy endpoint", 
      "high bleeding risk", 
      "retrospective cohort study", 
      "DAPT discontinuation", 
      "antiplatelet therapy", 
      "discontinuation group", 
      "DAPT duration", 
      "efficacy endpoint", 
      "bleeding risk", 
      "cohort study", 
      "coronary intervention", 
      "anticoagulant use", 
      "index percutaneous coronary intervention", 
      "acute coronary syndrome", 
      "history of MI", 
      "multivariate regression analysis", 
      "medical information database", 
      "ischemic risk", 
      "minor bleeding", 
      "gastrointestinal bleeding", 
      "coronary syndrome", 
      "cerebral infarction", 
      "ischemic events", 
      "major efficacy", 
      "clinical outcomes", 
      "atrial fibrillation", 
      "landmark analysis", 
      "patients", 
      "kidney disorders", 
      "composite efficacy", 
      "Japanese hospitals", 
      "discontinuation", 
      "event rates", 
      "study period", 
      "safety events", 
      "endpoint", 
      "months", 
      "bleeding", 
      "regression analysis", 
      "therapy", 
      "risk", 
      "efficacy", 
      "duration", 
      "intervention", 
      "determined factors", 
      "group", 
      "analysis group", 
      "infarction", 
      "fibrillation", 
      "syndrome", 
      "hospital", 
      "incidence", 
      "dialysis", 
      "information database", 
      "history", 
      "disorders", 
      "age", 
      "outcomes", 
      "study", 
      "conclusion", 
      "events", 
      "MI", 
      "years", 
      "use", 
      "period", 
      "factors", 
      "differences", 
      "database", 
      "occurrence", 
      "rate", 
      "analysis", 
      "Japan", 
      "determination"
    ], 
    "name": "Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals", 
    "pagination": "465-474", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1145403453"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12928-021-00833-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35141843"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12928-021-00833-z", 
      "https://app.dimensions.ai/details/publication/pub.1145403453"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_956.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12928-021-00833-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12928-021-00833-z'


 

This table displays all metadata directly associated to this object as RDF triples.

225 TRIPLES      21 PREDICATES      115 URIs      104 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12928-021-00833-z schema:about N0af44e7aa86e4f53ac7516324d142c54
2 N1fc63117f60f4756ba6654cc0fc214c9
3 N387d54b2a7864ae59116e7bcbd875f28
4 N4081a5710c574f07b5e7662235630a3e
5 N55f09d952d404118a84b736415894a66
6 N5701e63538a6428698a12e0c18b2b6c0
7 N842891796baa493095f9e9efa155f99a
8 N8a9fccc51c2b4e36ae08ab97c8185c06
9 Nab1a6029f389458eb302f27e0f09e63f
10 Nb4fabd6c32154784b0da912298edcfe9
11 Nc4fd2d23a7344e888a96eb67b18880f8
12 Ned811b83747040189fe70b817a59606b
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author N95a86b6c314e47efbf53d7be7b63da4b
16 schema:citation sg:pub.10.1007/s00392-020-01708-8
17 sg:pub.10.1007/s11239-018-1707-1
18 sg:pub.10.1038/nrcardio.2014.104
19 schema:datePublished 2022-02-09
20 schema:datePublishedReg 2022-02-09
21 schema:description In this real-world, retrospective cohort study of 9753 patients in Japan prescribed dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), we investigated DAPT duration and determined factors associated with early DAPT discontinuation and with event rates in patients who discontinued DAPT. The study period was April 1, 2012–March 31, 2018; endpoints comprised composite efficacy [death, myocardial infarction (MI), and stroke] and bleeding (intracranial, gastrointestinal, and requiring transfusion) endpoints. Overall, 68.8% of patients were continuing DAPT at 3 months post-PCI. Patients without major efficacy or safety events within 3 months after index PCI were included in a landmark analysis set (LAS; n = 7056), and categorized as DAPT ≥ 3 months (continuation) versus < 3 months (discontinuation). In the two LAS analysis groups, there was no difference in the composite bleeding endpoint (P = 0.067), although the incidence of the composite efficacy endpoint was higher in the discontinuation group (P < 0.001). In multivariate regression analysis, age ≥ 75 years, minor bleeding after PCI, history of cerebral infarction, history of cerebral or gastrointestinal bleeding, atrial fibrillation, dialysis, and anticoagulant use after PCI were associated with early DAPT discontinuation. Acute coronary syndrome, history of MI, kidney disorder, and anticoagulant use after PCI were associated with the composite efficacy endpoint in the discontinuation group. In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.
22 schema:genre article
23 schema:isAccessibleForFree true
24 schema:isPartOf N733c06ed8ee34a93a380ca018cd46682
25 Nca9b049cd7964fab878f441894520e0c
26 sg:journal.1042779
27 schema:keywords DAPT discontinuation
28 DAPT duration
29 Japan
30 Japanese hospitals
31 MI
32 acute coronary syndrome
33 age
34 analysis
35 analysis group
36 anticoagulant use
37 antiplatelet therapy
38 atrial fibrillation
39 bleeding
40 bleeding risk
41 cerebral infarction
42 clinical outcomes
43 cohort study
44 composite efficacy
45 composite efficacy endpoint
46 conclusion
47 coronary intervention
48 coronary syndrome
49 database
50 determination
51 determined factors
52 dialysis
53 differences
54 discontinuation
55 discontinuation group
56 disorders
57 dual antiplatelet therapy
58 duration
59 efficacy
60 efficacy endpoint
61 endpoint
62 event rates
63 events
64 factors
65 fibrillation
66 gastrointestinal bleeding
67 group
68 high bleeding risk
69 history
70 history of MI
71 hospital
72 incidence
73 index percutaneous coronary intervention
74 infarction
75 information database
76 intervention
77 ischemic events
78 ischemic risk
79 kidney disorders
80 landmark analysis
81 major efficacy
82 medical information database
83 minor bleeding
84 months
85 multivariate regression analysis
86 occurrence
87 outcomes
88 patients
89 percutaneous coronary intervention
90 period
91 rate
92 regression analysis
93 retrospective cohort study
94 risk
95 safety events
96 study
97 study period
98 syndrome
99 therapy
100 use
101 years
102 schema:name Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
103 schema:pagination 465-474
104 schema:productId N3b0f2792d2ec4037b2ef84276b575792
105 N491fa1c4aad74708b97533d39307b364
106 Nc1f8c2064f5b4477a85fabec14c594f6
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145403453
108 https://doi.org/10.1007/s12928-021-00833-z
109 schema:sdDatePublished 2022-11-24T21:09
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher Ne2e20774b3fa4b09b8d3753391399fe2
112 schema:url https://doi.org/10.1007/s12928-021-00833-z
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N0af44e7aa86e4f53ac7516324d142c54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N1fc63117f60f4756ba6654cc0fc214c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Aged
121 rdf:type schema:DefinedTerm
122 N387d54b2a7864ae59116e7bcbd875f28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Retrospective Studies
124 rdf:type schema:DefinedTerm
125 N3b0f2792d2ec4037b2ef84276b575792 schema:name doi
126 schema:value 10.1007/s12928-021-00833-z
127 rdf:type schema:PropertyValue
128 N3e5847bf2b404eb592c0c5474e81b4ed rdf:first Nc481ecdb50464e688a5c0960b7cbf271
129 rdf:rest rdf:nil
130 N4081a5710c574f07b5e7662235630a3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Myocardial Infarction
132 rdf:type schema:DefinedTerm
133 N491fa1c4aad74708b97533d39307b364 schema:name dimensions_id
134 schema:value pub.1145403453
135 rdf:type schema:PropertyValue
136 N55f09d952d404118a84b736415894a66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Drug Therapy, Combination
138 rdf:type schema:DefinedTerm
139 N5701e63538a6428698a12e0c18b2b6c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Percutaneous Coronary Intervention
141 rdf:type schema:DefinedTerm
142 N733c06ed8ee34a93a380ca018cd46682 schema:volumeNumber 37
143 rdf:type schema:PublicationVolume
144 N842891796baa493095f9e9efa155f99a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Gastrointestinal Hemorrhage
146 rdf:type schema:DefinedTerm
147 N8a9fccc51c2b4e36ae08ab97c8185c06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Treatment Outcome
149 rdf:type schema:DefinedTerm
150 N95a86b6c314e47efbf53d7be7b63da4b rdf:first sg:person.01052603744.16
151 rdf:rest Nc953e865caea408d99fd251cd5b9c094
152 Nab1a6029f389458eb302f27e0f09e63f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Platelet Aggregation Inhibitors
154 rdf:type schema:DefinedTerm
155 Nb4fabd6c32154784b0da912298edcfe9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Japan
157 rdf:type schema:DefinedTerm
158 Nc1f8c2064f5b4477a85fabec14c594f6 schema:name pubmed_id
159 schema:value 35141843
160 rdf:type schema:PropertyValue
161 Nc481ecdb50464e688a5c0960b7cbf271 schema:affiliation grid-institutes:grid.410844.d
162 schema:familyName Matsubayashi
163 schema:givenName Kenta
164 rdf:type schema:Person
165 Nc4fd2d23a7344e888a96eb67b18880f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Anticoagulants
167 rdf:type schema:DefinedTerm
168 Nc953e865caea408d99fd251cd5b9c094 rdf:first sg:person.016464605275.48
169 rdf:rest Ndb89a04202574c51b925736393f523d2
170 Nca9b049cd7964fab878f441894520e0c schema:issueNumber 3
171 rdf:type schema:PublicationIssue
172 Ndb89a04202574c51b925736393f523d2 rdf:first sg:person.013473141311.02
173 rdf:rest N3e5847bf2b404eb592c0c5474e81b4ed
174 Ne2e20774b3fa4b09b8d3753391399fe2 schema:name Springer Nature - SN SciGraph project
175 rdf:type schema:Organization
176 Ned811b83747040189fe70b817a59606b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Hospitals
178 rdf:type schema:DefinedTerm
179 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
180 schema:name Medical and Health Sciences
181 rdf:type schema:DefinedTerm
182 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
183 schema:name Clinical Sciences
184 rdf:type schema:DefinedTerm
185 sg:journal.1042779 schema:issn 1868-4297
186 1868-4300
187 schema:name Cardiovascular Intervention and Therapeutics
188 schema:publisher Springer Nature
189 rdf:type schema:Periodical
190 sg:person.01052603744.16 schema:affiliation grid-institutes:grid.411731.1
191 schema:familyName Yokoi
192 schema:givenName Hiroyoshi
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052603744.16
194 rdf:type schema:Person
195 sg:person.013473141311.02 schema:affiliation grid-institutes:None
196 schema:familyName Kaneko
197 schema:givenName Kazuki
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013473141311.02
199 rdf:type schema:Person
200 sg:person.016464605275.48 schema:affiliation grid-institutes:None
201 schema:familyName Oda
202 schema:givenName Eisei
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016464605275.48
204 rdf:type schema:Person
205 sg:pub.10.1007/s00392-020-01708-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1129531993
206 https://doi.org/10.1007/s00392-020-01708-8
207 rdf:type schema:CreativeWork
208 sg:pub.10.1007/s11239-018-1707-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105133084
209 https://doi.org/10.1007/s11239-018-1707-1
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/nrcardio.2014.104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039569766
212 https://doi.org/10.1038/nrcardio.2014.104
213 rdf:type schema:CreativeWork
214 grid-institutes:None schema:alternateName EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan
215 StatLink Medical Statistics Consulting Service, Tokyo, Japan
216 schema:name EBM Unit, Medical Data Vision Co., Ltd., Tokyo, Japan
217 StatLink Medical Statistics Consulting Service, Tokyo, Japan
218 rdf:type schema:Organization
219 grid-institutes:grid.410844.d schema:alternateName Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
220 schema:name Clinical Development Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan
221 rdf:type schema:Organization
222 grid-institutes:grid.411731.1 schema:alternateName International University of Health and Welfare, Tochigi, Japan
223 schema:name Cardiovascular Medicine Center, Fukuoka Sanno Hospital, 3-6-45 Momochihama, Sawara-ku, 814-0001, Fukuoka, Japan
224 International University of Health and Welfare, Tochigi, Japan
225 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...